Evidence map›Paper›PMID 41719743›Full record

ArticleStem cell research2026

Generation of two isogenic sickle cell disease induced pluripotent stem cell lines from ovarian fibroblasts.

Mitchell R Harancher, Livianna K Myklebust, Meena Sukhwani, Charvi Kanodia, Yi Sheng, Carlos A Castro, Amanda M Colvin Zielen, Kyle E Orwig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mitchell R HarancherMolecular Genetics and Developmental Biology Graduate Program, University of Pittsburgh, PA, United States; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA.
Livianna K MyklebustMolecular Genetics and Developmental Biology Graduate Program, University of Pittsburgh, PA, United States; Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA, USA.
Meena SukhwaniDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA.
Charvi KanodiaUniversity of Edinburgh Medical School, Edinburgh, Scotland, UK; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA.
Yi ShengDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA.
Carlos A CastroDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA.
Amanda M Colvin ZielenDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA; UPMC Magee Center for Reproduction and Transplantation, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Kyle E OrwigMolecular Genetics and Developmental Biology Graduate Program, University of Pittsburgh, PA, United States; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh Medical Center, USA; UPMC Magee Center for Reproduction and Transplantation, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: orwigke@upmc.edu.

Funding

Project IIIP50HD096723 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DONALD F. CONRAD · 2019 to 2026
$15.0M
NICHD NIH HHS P50 HD096723
6 · The paper itself

Abstract

Curative bone marrow transplantation (BMT) therapies for sickle cell disease (SCD) can cause infertility. The Fertility Preservation Program (FPP) in Pittsburgh cryopreserves ovarian tissues for SCD patients prior to BMT in anticipation that these tissues can be used in the future to produce eggs and achieve a pregnancy. Here, we generated and validated two isogenic patient-derived induced pluripotent stem cell (iPSC) lines from ovarian cortex fibroblasts of a 28-year-old SCD patient.

Indexed as

Anemia, Sickle CellFibroblastsInduced Pluripotent Stem CellsOvaryAdultCell LineFemaleHumans

Identifiers

PMID41719743
PMCPMC13077771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.